Oral ftorafur plus intramuscular thiotepa as adjuvant chemotherapy in patients with breast cancer.
In this study, we evaluated the safety and efficacy of a combination of oral ftorafur administered together with intramuscular thiotepa as adjuvant chemotherapy for "early" breast cancer patients. A total of 30 patients with operated breast cancer were treated with 500 mg/m2 oral ftorafur for 10 consecutive days plus 20 mg/m2 intramuscular (im) administered thiotepa on d 1 and 8 every 28 d adjuvant chemotherapy. Eleven patients were premenopausal and 19 were postmenopausal, with a median age of 53 yr. The total number of cycles delivered was 259 (median: 10 cycles per patient). Toxicity was low and usually consisted of leukopenia WHO grade I-II (14%) and neutropenia grade I-II (6%). Gastrointestinal toxicity was minimal. The 5-yr disease-free survival and overall survival were 55% and 84%, respectively. Relapse occurred as bone metastases (50%), local recurrence (25%), and liver (17%) and brain (8%) metastases. Our preliminary data showed that oral ftorafur and im thiotepa is a well-tolerated regimen and could be a useful alternative to the intravenous parenteral route as adjuvant treatment for early breast cancer. Randomized trials are needed to assess the possible advantage of this regimen over intravenous schedules.
Galmarini
C M
CM
Division Medicina, Hospital Municipal de Oncologia María Curie, Buenos Aires, Argentina. fgalma@rockefeller.univ-lyon1.fr
Garbovesky
C
C
Galmarini
D
D
Galmarini
F C
FC
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects; D013852:Thiotepa / Q000008:administration & dosage* / Q000009:adverse effects
D005641:Tegafur; D013852:Thiotepa